Halozyme Therapeutics, Inc. has announced interim results from a proof of concept Phase I/II clinical trial evaluating the activity and local tolerability of HTI-501, an investigational biologic, for use in

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In